• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Residual Risk Odyssey: From LDL to Lp(a).

作者信息

Rosenson Robert S, Goonewardena Sascha N

机构信息

Metabolism and Lipids Unit, Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Icahn School of Medicine, New York, New York, USA.

Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

J Am Coll Cardiol. 2021 Aug 3;78(5):434-436. doi: 10.1016/j.jacc.2021.04.103.

DOI:10.1016/j.jacc.2021.04.103
PMID:34325832
Abstract
摘要

相似文献

1
The Residual Risk Odyssey: From LDL to Lp(a).残余风险探索之旅：从低密度脂蛋白到脂蛋白(a)
J Am Coll Cardiol. 2021 Aug 3;78(5):434-436. doi: 10.1016/j.jacc.2021.04.103.
2
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.脂蛋白(a)与前蛋白转化酶枯草溶菌素/kexin 9型抑制剂
Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):45-50. doi: 10.1007/s11789-019-00099-z.
3
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.急性冠状动脉综合征后外周动脉疾病和静脉血栓栓塞事件：脂蛋白(a)的作用和依洛尤单抗的修饰：ODYSSEY OUTCOMES 随机临床试验的预设分析。
Circulation. 2020 May 19;141(20):1608-1617. doi: 10.1161/CIRCULATIONAHA.120.046524. Epub 2020 Mar 29.
4
Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.在一般人群中，血清前蛋白转化酶枯草溶菌素 9（PCSK9）与胰岛素抵抗、甘油三酯、脂蛋白（a）水平独立相关，但与低密度脂蛋白胆固醇水平无关。
J Atheroscler Thromb. 2021 Apr 1;28(4):329-337. doi: 10.5551/jat.56390. Epub 2020 Jul 4.
5
Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.载脂蛋白(a)降低后 LDL-C、估计真实 LDL-C、载脂蛋白 B-100 和 PCSK9 水平的关系。 采用反义寡核苷酸。
J Clin Lipidol. 2018 May-Jun;12(3):702-710. doi: 10.1016/j.jacl.2018.02.014. Epub 2018 Mar 1.
6
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.载脂蛋白(a)表型决定了潜在家族性高胆固醇血症患者脂蛋白(a)和前蛋白转化酶枯草溶菌素/克那霉 9 水平的相关性。
Atherosclerosis. 2018 Oct;277:477-482. doi: 10.1016/j.atherosclerosis.2018.08.011.
7
Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.血浆脂蛋白相关磷脂酶 A2 与前蛋白转化酶枯草溶菌素 9 呈负相关。
Arch Med Res. 2012 Jan;43(1):11-4. doi: 10.1016/j.arcmed.2012.01.001. Epub 2012 Jan 31.
8
Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.依洛尤单抗降低 PCSK9 治疗后 LDL-C 与脂蛋白(a)的关系。
J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932.
9
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.阿托伐他汀、胆固醇酯转移蛋白抑制和糖尿病对高心血管风险患者循环前蛋白枯草溶菌素 9 和脂蛋白(a)水平的影响。
J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12.
10
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.大剂量阿托伐他汀与瑞舒伐他汀对急性冠状动脉综合征患者血脂参数、氧化型低密度脂蛋白及枯草溶菌素9型前蛋白转化酶的比较作用
Coron Artery Dis. 2019 Jun;30(4):285-290. doi: 10.1097/MCA.0000000000000715.

引用本文的文献

1
Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease.脂蛋白(a)在动脉粥样硬化性心血管疾病中整合单核细胞介导的血栓形成和炎症反应。
J Lipid Res. 2025 Jun;66(6):100820. doi: 10.1016/j.jlr.2025.100820. Epub 2025 May 5.
2
Prevalence of Lipoprotein(a) Measurement and its Association with Arteriosclerosis in Asymptomatic Individuals in China.中国无症状个体中脂蛋白(a)检测的患病率及其与动脉硬化的关联
J Atheroscler Thromb. 2025 Apr 1;32(4):513-524. doi: 10.5551/jat.65214. Epub 2024 Oct 22.
3
Lipoprotein(a): a Case for Universal Screening in Youth.
脂蛋白(a)：在青年人群中进行普遍筛查的理由。
Curr Atheroscler Rep. 2023 Aug;25(8):487-493. doi: 10.1007/s11883-023-01120-3. Epub 2023 Jul 5.
4
Role of lipoprotein(a) in plaque progression.脂蛋白(a)在斑块进展中的作用。
Eur Heart J Suppl. 2022 Nov 12;24(Suppl I):I72-I75. doi: 10.1093/eurheartjsupp/suac071. eCollection 2022 Nov.
5
Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.家族性高胆固醇血症与脂蛋白(a)升高：级联检测及对情境化照护模式的其他影响
Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022.
6
Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism.高胆固醇血症与2019冠状病毒病：他汀类药物用于降低静脉血栓栓塞风险
Front Cardiovasc Med. 2021 Oct 13;8:711923. doi: 10.3389/fcvm.2021.711923. eCollection 2021.